This is a preview of subscription content, log in via an institution to check access.
Reference
Wolford JE, et al. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecologic Oncology : 13 Mar 2020. Available from: URL: http://doi.org/10.1016/j.ygyno.2020.02.030
Rights and permissions
About this article
Cite this article
Novel therapies for recurrent ovarian cancer: modest benefits at high cost. PharmacoEcon Outcomes News 850, 29 (2020). https://doi.org/10.1007/s40274-020-6717-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6717-5